Company: SION
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0002036042-25-000016
Chunk: 208

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 208
---
— (16,482)(16,482)Balance at March 31, 2025—$— —$— —$— —$— 44,092,117$44 $548,992 $301 $(197,568)$351,769 

Series SeedSeries ASeries BSeries C Common Stock AdditionalPaid-InCapitalAccumulatedOtherComprehensiveLossAccumulatedDeficitTotalStockholders’DeficitPreferred Stock Preferred StockPreferred Stock Preferred Stock SharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance at December 31, 20233,963,963$13,014 5,704,161$25,235 11,370,621$110,791 —$— 3,050,863$2 $4,515 $— $(119,398)$(114,881)Issuance of Series C Preferred Stock, net of issuance costs of $528—— —— —— 18,628,970181,328 —— — — — — Exercise of common stock options—— —— —— —— 821— 5 — — 5 Vesting of restricted common stock awards—— —— —— —— 51,1851 — — — 1 Stock-based compensation expense—— —— —— —— —— 647 — — 647 Unrealized loss on marketable securities—— —— —— —— —— — (8)— (8)Net loss—— —— —— —— —— — — (11,847)(11,847)Balance at March 31, 20243,963,963$13,014 5,704,161$25,235 11,370,621$110,791 18,628,970$181,328 3,102,869$3 $5,167 $(8)$(131,245)$(126,083)

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-4

Table of Contents

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands) 

(Unaudited)Three Months EndedMarch 31,20252024Cash flows from operating activities:Net loss$(16,482)$(11,847)Adjustments to reconcile net loss